I know your comments / questions are not directed at me. But, sometimes I feel that there needs to be some clear facts thorwn here and there once in a while so people don't perpetuate the misinformation or unfounded fear or assumptions, etc.

Is it possible that the COVID-19 Trial design is a bit much and too complicated to simply know if Apabetalone avoids the intensive care unit altogether?

I don't think so. There are some guidelines to follow to design the trials, e.g., WHO or FDA, etc.

And according to the trial, Apabetalone is to be administered BID with meals. Do they serve meals in the ICU? And does the standard of care administered to patients include monoclonal antibody treatment such as Remdesivir?

Patients admitted to ICU are excluded from the trial.